According to filings with the U.S. Securities and Exchange Commission, Nucleus Radiopharma is raising up to $6,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Charles Conroy played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nucleus Radiopharma
Transforming lives with radiopharmaceuticals by leveraging world class clinical, development, manufacturing, and supply chain expertise. Nucleus bridges the gap between innovation and clinic. Nucleus RadioPharma is a full-service Contract Development and Manufacturing Organization (CDMO) dedicated to building robust and reliable clinical and commercial supply chains for targeted radiotherapies. We are building our development and manufacturing facilities in proximity to prominent destination medical centers and key distribution hubs. Nucleus’ relationships will enable access to the world’s largest radiopharmaceutical clinical trial networks and provide timely delivery of short half-life theranostics products to patients. Our technology platforms and drug development expertise provide clients with end-to-end support – including formulation and analytical development, regulatory documentation, drug product manufacturing, and distribution to patients.

To learn more about Nucleus Radiopharma, visit http://www.nucleusrad.com/

Contact:
Charles Conroy, Chief Executive Officer
980-483-3788
https://www.linkedin.com/in/charlesconroyrph/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.